| Literature DB >> 34848944 |
Badriyah Shadid Alotaibi1, Munazza Ijaz2, Manal Buabeid3,4, Zelal Jaber Kharaba5, Hafiza Sidra Yaseen6, Ghulam Murtaza6.
Abstract
Polyphenols have long been recognized as health-promoting entities, including beneficial effects on cardiovascular disease, but their reputation has been boosted recently following a number of encouraging clinical studies in multiple chronic pathologies, that seem to validate efficacy. Health benefits of polyphenols have been linked to their well-established powerful antioxidant activity. This review aims to provide comprehensive and up-to-date knowledge on the current therapeutic status of polyphenols having sufficient heed towards the treatment of cardiovascular diseases. Furthermore, data about the safety profile of highly efficacious polyphenols has also been investigated to further enhance their role in cardiac abnormalities. Evidence is presented to support the action of phenolic derivatives against cardiovascular pathologies by following receptors and signaling pathways which ultimately cause changes in endogenous antioxidant, antiplatelet, vasodilatory, and anti-inflammatory activities. In addition, in vitro antioxidant and pre-clinical and clinical experiments on anti-inflammatory as well as immunomodulatory attributes of polyphenols have revealed their role as cardioprotective agents. However, an obvious shortage of in vivo studies related to dose selection and toxicity of polyphenols makes these compounds a suitable target for clinical investigations. Further studies are needed for the development of safe and potent herbal products against cardiovascular diseases. The novelty of this review is to provide comprehensive knowledge on polyphenols safety and their health claims. It will help researchers to identify those moieties which likely exert protective and therapeutic effects towards cardiovascular diseases.Entities:
Keywords: antioxidant; cardioprotective; cardiovascular diseases; clinical trials; polyphenols
Mesh:
Substances:
Year: 2021 PMID: 34848944 PMCID: PMC8619826 DOI: 10.2147/DDDT.S327238
Source DB: PubMed Journal: Drug Des Devel Ther ISSN: 1177-8881 Impact factor: 4.162
Topology and a Brief Description of CVDs
| Disease Name | Pathological Mechanism | Risk Factors | References |
|---|---|---|---|
| Coronary heart disease | Narrowing of coronary arteries due to fatty deposits, which limits blood flow to cardiac myocytes. | Atherosclerosis, unhealthy food, lack of exercise, and smoking | [ |
| Cerebrovascular disease | Brain cells do not get enough oxygen and ischemic stroke or embolism may result | Comorbidities (Hypertension, Obesity, Diabetes mellitus, Hypercholesterolemia), poor diet, tobacco usage | [ |
| Rheumatic heart disease | Damage of heart valves due to rheumatic fever | Untreated streptococcal infections | [ |
| Congenital heart disease | Defect present at birth in hearts walls, valves, and blood vessel in the supply of blood to the heart and whole body | Alcohol abuse, smoking, chromosomal defects | [ |
Figure 1General classification of phenols.
Figure 2Flowchart summary of the systematic review process.
Figure 3Percentage of botanical families having potential towards cardiovascular diseases.
Summary of Different Plants Derived Polyphenols Having a Cardioprotective Effect
| Sr. No | Plant Name | Family | Polyphenolic Compound | References | |
|---|---|---|---|---|---|
| 1 | Quercetin, Apigenin-7-glucoside, Verbascoside, | [ | |||
| 2 | Luteolin-7-O-glycone, Chlorogenic acid, Rutin, Apigenin-7-O-glucoside | [ | |||
| 3 | Chlorogenic acid, Vicenin-2, Luteolin-3-,7-di-O-glucoside, Luteolin-7-O-glucoside, Rutin, Apigenin-7-O-glucoside, Luteolin, Apigenin | [ | |||
| 4 | Catechin, Cyanidin, Delphinidin, Ellagic acid, Gallic acid, isoquercetin, Ursolic acid, oleanolic acid, | [ | |||
| 5 | Caffeic acid, Quercetin, Kaempferol, Apigenin | [ | |||
| 6 | Cryptochlorogenic acid, Homovanillic acid, Kaempferol, Ferulic acid, Gallic acid, Vanillic acid, Naringin-c-hexoside, Hesperidin, Hesperetin | [ | |||
| 7 | Benzophenone, Iriflophenone-2-O-α-L-rhamnopyranoside, Rosmarinic acid, Rosmarinic acid methyl ester, salvianolic acid A methyl ester, salvianolic acid A ethyl ester, | ||||
| 8 | Caffeic acid, Protocatechuic acid, Coumaric acid-O-hexoside, Cryptochlorogenic acid, Rosmarinic acid-O-hexoside, Ferulic acid, Gallic acid, Vanillic acid, Naringin-c-hexoside, Hesperidin, Hesperetin | [ | |||
| 9 | Cinnamic acid, Caffeic acid, Rosmarinic acid, Protocatechuic acid | [ | |||
| 10 | Caffeic acid, chebulagic acid, chebulinic acid | ||||
| 11 | Catechin, Caffeic acid, Ferulic acid, Syringic acid, Cinnamic acid, Quercetin, Vanillic acid, Chlorogenic acid, Luteolin, Apigenin | ||||
| 12 | Vanillic acid, Ferulic acid, Kaempferol, Quercetin, Acacetin | [ | |||
| 13 | Phloretin, Neochlorogenic acid, Feruloylquinic acid, Quercetin, | [ | |||
| 14 | Ellagic acid, catechin, pelargonidin-3-rutinoside, cyanidin diglucoside | [ | |||
| 15 | Naringin, kaempferol, Luteolin, apigenin, caffeic acid, ferulic acid, Syringic acid | [ | |||
| 16 | Vanillic acid, | [ | |||
| 17 | Anthocyanins, | [ | |||
| 18 | Flavanones, Flavonols, Flavones, Anthocyanins, coumestans, pterocarpans | [ | |||
| 19 | Catechin, Cyanidin, Delphinidin, Ellagic acid, Gallic acid, isoquercetin, Ursolic acid, oleanolic acid | [ | |||
| 20 | Catechin, Anthocyanins, Epicatechin, Catechin, Proanthocyanidins, cyanidin-3-α-L-arabinoside, Gallocatechin | [ | |||
| 21 | Quercetin, | [ | |||
| 22 | Quercetin, Quinic acid, Caffeoyl glucose, Feruloylquinic acid, Catechin, Quercetin-3-O-rutinoside | [ | |||
| 23 | Rutin, Catechin, Quercetin, Isorhamnetin, Kaempferol | [ | |||
| 24 | Quercetin-3-O-rutinoside, Luteolin-7-O-glucoside, Luteolin-4ʹ-O-glucoside, Apigenin-7-O-glucoside | [ | |||
| 25 | Resveratrol, Epigallocatechin-3-gallate, Quercetin, Anthocyanins, Procyanidins, Catechin, Epigallocatechin, | [ | |||
Figure 4Possible mechanisms of polyphenols in the prevention of cardiovascular diseases.
Figure 5Hazards related to polyphenols.
Safety Profile and Related Effects of Plants-Sourced Polyphenols
| Polyphenolic Compounds | Dose | Pharmacological Effects | References |
|---|---|---|---|
| Gallic acid | 5000 mg/kg via oral route in an acute toxicity study | Non-toxic | [ |
| Clovinol | 1,000 mg/kg b.w in subchronic toxicity study | Non-toxic | [ |
| Curcumin | 2,000–5,000 mg/kg | No adverse effects | [ |
| Rutin | Up to 5,000 mg/kg | Non-toxic | [ |
| Naringin | 1,250 mg/kg for period of 6 months (chronic toxicological studies) | Hair loss, decrease in body weight and food consumption | [ |
| Myricitrin | 200, 500, and 1,000 mg/kg in rats | No toxic effects | |
| Resveratrol | A higher dose of 1 mg/kg | Hypercholesterolemia-related atherosclerosis | [ |
| 1,000 and 3,000 mg/kg | Renal toxicity and nephropathy, reduction in weight of lungs and heart | [ | |
| Lower dose 300 µg/mL | Non-toxic, good antioxidant | [ | |
| Quercetin | 2, 4, 6 g/kg | No acute toxic effects | [ |
| 8 g/kg | Neurotoxicity along with disruption of BBB and cause jerks as well as writhes | [ | |
| Epigallocatechin gallate | 50 µM | Neurotoxicity along with disruption of BBB | [ |
| Cyanidin-3-glucoside | 50 µM | Neurotoxicity along with disruption of BBB | [ |
| Benzoic acid | 800 mg/kg body weight orally | Low toxicity level | [ |
| Higher dose >800 mg/kg | Weight gain, lesions in kidneys, lungs, skeletal muscles, stomach | [ | |
| Kaempferol | 8 g/kg | No acute toxic effects | [ |
Plants Derived Natural Polyphenols in Pre-Clinical and Clinical Trials Against Cardiovascular Diseases
| Compound Name | Experimental Model and Dose | Mechanism | Pharmacological Effect | References |
|---|---|---|---|---|
| Resveratrol | Randomized study on 34 patients with metabolic syndrome (100 mg resveratrol with a combination of quercetin and vitamin D3 and rice bran) | Increased in blood flow-mediated dilation and improved endothelial dysfunction | Anti-inflammatory, Antihypertensive, Lipid-lowering agent | [ |
| Placebo controlled double-blind randomized study on hypertensive patients (n=24) with metabolic syndrome (300 mg resveratrol OD) | Improved function of endothelium function and no effects on blood pressure and augmentation index | Anti-inflammatory, Hypercholesterolemia agent and lipid-lowering drug, Cardioprotective | [ | |
| Triple blind randomized placebo-controlled study on 75 stable coronary artery disease patients with metabolic syndrome (370 mg resveratrol capsule with 350 mg | Decreased lipid peroxidation and levels of ROS | Cardiovascular effects | [ | |
| Curcumin | Randomized controlled trials double-blind trial (70 mg/day curcuminoids) | Increased cell viability and mitochondrial protection. Also, decrease apoptosis | Anti-inflammatory, Hypercholesterolemia, antioxidant | [ |
| Catechin and Epicatechins | A perspective cohort study on women (34,492) for 13 years. Catechin | Decreased lipid peroxidation and levels of ROS | Anti-inflammatory, antioxidant, Cardioprotective effects, impedes coronary artery disease | [ |
Comparison of Different Doses of Quercetin and Its Derivatives as a Cardioprotective Agent
| Compound Name | Experimental Model | Mechanism | Pharmacological Effect | References |
|---|---|---|---|---|
| Quercetin | Isoproterenol induced myocardial infarction in rats (20 mg/kg) | Decrease reactive oxygen species and levels of calpain | Decrease inflammation and oxidative stress | [ |
| Diabetic cardiomyopathy in rats (10–50 mg/kg) | Decrease troponin levels, low-density lipoproteins, caspases 3 and 9 | Decrease cardiac damage, inflammation, apoptosis and increase cell viability | [ | |
| Troxerutin | In vivo rat model by inducing ischemia-reperfusion (150 mg/kg) | Decrease levels of IL-1b, ICAM-1 and TNF-alpha | Decrease infarct size, arrhythmia and inflammation ultimately increase cardiac function | [ |
| Iso-quercetin | In vitro assay on H9c2 cells by inducing ischemia-reperfusion (20–80 µM/mL) | Decrease ROS generation and cytochrome-c release | Increase cell viability and mitochondrial protection. Also, decrease apoptosis | [ |
| Isorhamnetin | In vitro assay on H9c2 cells by inducing ischemia-reperfusion (10–40 µM/mL) | Decrease caspases 3, cytochrome-c release and reactive oxygen species | Enhance mitochondrial protection and decrease oxidative damage | [ |
| Dihydro-quercetin | In vitro assay (H9c2 cells) and in vivo rat model by inducing ischemia-reperfusion (5–20 µM/mL) | Decrease apoptosis and oxidative stress | Decrease ROS, ER stress and PI3K/Akt | [ |
Comparison of Different Doses of Naringin and Its Derivatives in Cardiovascular Diseases
| Compound Name | Experimental Model and Dose | Mechanism | Pharmacological Effect | References |
|---|---|---|---|---|
| Naringin | High-fat diet-induced rat model (100 mg/kg body weight) | Ameliorated functioning of endothelium by enhancing bioavailability of NO (nitric oxide) Moreover, exert therapeutic effects against prolonged inflammation by decreasing levels of inflammatory mediators intracellularly | Decrease blood pressure and treat hypertension | [ |
| Stroke-prone hypertensive Wistar rats (200, 500, and 1,000 mg/kg) | Ameliorated functioning of endothelium by enhancing bioavailability of NO (nitric oxide) | Decrease cardiac damage and hypertension | [ | |
| Isoproterenol induced myocardial infarction in rats (10, 20, and 40 mg/kg) | Decreased lipid peroxidation and levels of ROS | Cardioprotective agent | [ | |
| Doxorubicin-induced cardiotoxicity (10 mg/kg body weight) | The reduced serum concentration of AST, LDH, and CK-MB | Protected against cardiotoxicity | [ | |
| Naringenin | In vitro assay on H9c2 cardiomyocyte cells | Naringenin produced an inhibitory effect against daunorubicin apoptosis of H9c2 cardiomyocyte cells | Decreased inflammation ultimately increase cardiac function | [ |